Everything tagged "biopharma" across the TickerSpark archives.
AstraZeneca’s oncology and respiratory franchises are offsetting legacy erosion, supporting a Buy rating despite leverage and trial risk. The stock looks reasonably valued with multiple late-stage catalysts still ahead.
AbbVie is successfully replacing Humira with fast-growing immunology and neuroscience assets, supporting a Buy view despite heavy debt and a rich valuation. Skyrizi, Rinvoq, and neuroscience growth are offsetting legacy erosion and keeping earnings momentum intact.
Novo Nordisk still pairs elite profitability with strong obesity growth, but U.S. pricing pressure is tempering the once-clean hypergrowth story. The Wegovy pill and broader cardiometabolic pipeline keep the long-term case intact.
Sanofi is becoming a more focused biopharma compounder, led by Dupixent growth, vaccine strength, and expanding launch sales. The stock looks inexpensive versus its cash generation and earnings power.
GSK is evolving from a mature pharma cash generator into a more balanced growth story, with Specialty Medicines driving faster growth and margins improving. The stock still looks reasonably valued versus its earnings power and pipeline.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime